Tryp Therapeutics Readies First Trial of TRP-8802 for Excessive Appetite

Tryp Therapeutics Readies First Trial of TRP-8802 for Excessive Appetite

286153

Tryp Therapeutics Readies First Trial of TRP-8802 for Excessive Appetite

Tryp Therapeutics announced plans to launch a Phase 2a clinical trial evaluating the potential of its investigational oral candidate TRP-8802 (synthetic psilocybin) at reducing excessive appetite in people with Prader-Willi syndrome (PWS) and other rare disorders characterized by overeating and with high unmet therapeutic needs. The upcoming trial is being designed in collaboration with Jennifer Miller, MD, a pediatric endocrinologist specialized in PWS and other genetic causes of early-onset excessive weight gain. Miller will be the trial’s…

You must be logged in to read/download the full post.